Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 430 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer (EOC) MOST POPULAR Blood Test Accurately Detects Early-Stage Pancreatic Cancer May 10, 2024 Skin cancer death rates in men risen dramatically in the last... July 14, 2022 A celebration of peer review September 21, 2021 Age: the forgotten cancer risk factor? May 29, 2023 Load more HOT NEWS Sharing Energy VA Study Finds No Disparities in Prostate Cancer Deaths with Equal... Cancer vaccines – where are we? Study Suggests Watching Disney Movies May Improve Quality of Life for...
